HomeCompareBIOC vs PLD

BIOC vs PLD: Dividend Comparison 2026

BIOC yields 459.88% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BIOC wins by $32347.28M in total portfolio value
10 years
BIOC
BIOC
● Live price
459.88%
Share price
$0.43
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32353.19M
Annual income
$22,660,147,667.77
Full BIOC calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — BIOC vs PLD

📍 BIOC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBIOCPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BIOC + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BIOC pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIOC
Annual income on $10K today (after 15% tax)
$39,089.45/yr
After 10yr DRIP, annual income (after tax)
$19,261,125,517.60/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, BIOC beats the other by $19,257,087,401.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIOC + PLD for your $10,000?

BIOC: 50%PLD: 50%
100% PLD50/50100% BIOC
Portfolio after 10yr
$16179.55M
Annual income
$11,332,449,196.48/yr
Blended yield
70.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

BIOC
Analyst Ratings
1
Buy
2
Hold
Consensus: Hold
Altman Z
-24.7
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIOC buys
0
PLD buys
0
No recent congressional trades found for BIOC or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBIOCPLD
Forward yield459.88%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$32353.19M$5.91M
Annual income after 10y$22,660,147,667.77$4,750,725.19
Total dividends collected$31493.31M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: BIOC vs PLD ($10,000, DRIP)

YearBIOC PortfolioBIOC Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$56,688$45,987.58$11,241$540.96+$45.4KBIOC
2$304,294$243,637.85$13,019$991.13+$291.3KBIOC
3$1,547,860$1,222,266.18$15,801$1,870.97+$1.53MBIOC
4$7,466,811$5,810,600.46$20,609$3,701.21+$7.45MBIOC
5$34,185,829$26,196,340.96$29,919$7,867.97+$34.16MBIOC
6$148,669,080$112,090,243.27$50,631$18,617.74+$148.62MBIOC
7$614,649,543$455,573,627.83$105,528$51,352.20+$614.54MBIOC
8$2,417,954,821$1,760,279,809.21$287,364$174,449.42+$2417.67MBIOC
9$9,058,914,211$6,471,702,552.56$1,081,760$774,280.77+$9057.83MBIOC
10$32,353,185,873$22,660,147,667.77$5,908,209$4,750,725.19+$32347.28MBIOC

BIOC vs PLD: Complete Analysis 2026

BIOCStock

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

Full BIOC Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this BIOC vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIOC vs SCHDBIOC vs JEPIBIOC vs OBIOC vs KOBIOC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.